GLP1R and diabetes mellitus: Taken together, for the first time, we have demonstrated that HBK001, a novel dual-target compound for GPR119 and DPP4, significantly improved glucose homeostasis and β-cell function by enhancing plasma GLP-1 levels and insulin secretion in β-cells, and therefore represents a very promising therapeutic candidate for diabetes treatment.